About unicycive therapeutics inc - UNCY
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
UNCY At a Glance
Unicycive Therapeutics, Inc.
4300 El Camino Real
Los Altos, California 94022
| Phone | 1-650-351-4495 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -26,555,000.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
UNCY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.226 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.748 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.004 |
UNCY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,264,523.81 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
UNCY Liquidity
| Current Ratio | 2.585 |
| Quick Ratio | 2.585 |
| Cash Ratio | 2.179 |
UNCY Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -65.728 |
| Return on Equity | -141.145 |
| Return on Total Capital | -87.363 |
| Return on Invested Capital | -140.707 |
UNCY Capital Structure
| Total Debt to Total Equity | 0.659 |
| Total Debt to Total Capital | 0.655 |
| Total Debt to Total Assets | 0.405 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |